Welcome to our dedicated page for Mei Pharma news (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on Mei Pharma stock.
The MEIP news page on Stock Titan provides an organized view of public announcements and regulatory disclosures related to MEI Pharma, Inc. and its transition to Lite Strategy, Inc. These items trace the company’s path from a clinical-stage oncology business with a portfolio of cancer drug candidates to an enterprise emphasizing a Litecoin-focused digital asset treasury strategy.
Earlier news releases describe MEI Pharma’s work as a pharmaceutical company with drug candidates such as voruciclib and ME-344, along with updates on cash position, research and development spending, and the evaluation of strategic alternatives. These reports document the company’s efforts to preserve cash, consider out-licensing and merger and acquisition options, and adjust its workforce and clinical programs while seeking to maximize asset value for stockholders.
More recent articles highlight a major strategic shift: the launch of a Litecoin treasury initiative, a large private placement to fund this strategy, and the acquisition of a substantial Litecoin position. The company’s news also details the appointment of digital asset advisors, board changes linked to its treasury focus, and the formal rebranding to Lite Strategy, Inc. with a new NASDAQ ticker symbol, LITS.
Investors and researchers using this page can follow how MEI Pharma’s oncology-focused narrative evolved into a digital asset treasury story, including key milestones such as the private placement, Litecoin acquisitions, and the corporate name and ticker change. For ongoing developments after the symbol transition, users should also review news associated with Lite Strategy, Inc. under its current trading symbol.
MEI Pharma and Kyowa Kirin have announced updated clinical data from a Phase 1b study of zandelisib, a selective PI3Kδ inhibitor, in combination with zanubrutinib, for patients with relapsed or refractory B-cell malignancies. This data will be presented at the European Hematology Association (EHA) 2021 Virtual Congress from June 9-17, 2021. The study aims to assess the drug combination's tolerability and efficacy, potentially leading to improved therapeutic options for patients. The abstract is accessible on the EHA website.
MEI Pharma, Inc. (NASDAQ: MEIP) reported Q3 results for the period ended March 31, 2021, revealing a net loss of $31.3 million, or $0.28 per share, compared to a loss of $4.3 million, or $0.04 per share the previous year. Revenue increased to $2.4 million from $1.2 million, largely due to a license agreement with Kyowa Kirin. Key advancements include the completion of enrollment in the TIDAL study for zandelisib and promising preclinical data for voruciclib. The company has $164.6 million in cash with no debt and aims to submit data to the FDA for accelerated approval by year-end.
MEI Pharma, Inc. (NASDAQ: MEIP) announced the retirement of its chief medical officer, Robert Mass, effective May 3, 2021. Dr. Mass, who joined MEI in 2010, will serve as a strategic advisor post-retirement. Richard Ghalie, previously senior vice president of clinical development, has been promoted to chief medical officer. Under Ghalie's leadership, MEI's zandelisib program has progressed significantly, with plans for a new drug application to the FDA under the accelerated approval pathway.
MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. have completed enrollment in the follicular lymphoma primary efficacy population for the global Phase 2 TIDAL study. This study evaluates zandelisib, a potential cancer treatment. The primary efficacy population includes 91 patients with follicular lymphoma and 64 with marginal zone lymphoma. Topline data is expected in Q4 2021, with plans to submit for FDA accelerated approval. Zandelisib holds Fast Track designation for adult patients with relapsed follicular lymphoma who have undergone at least two prior systemic therapies.
MEI Pharma, Inc. (NASDAQ: MEIP) announced promising preclinical data for voruciclib, a CDK9 inhibitor, showing its effectiveness against KRAS mutant cancers. The findings, presented at the AACR Annual Meeting 2021, reveal voruciclib's ability to inhibit MYC and synergistically enhance the efficacy of KRAS inhibitors. Currently in a Phase 1b trial for B-cell malignancies and AML, the data supports the potential for voruciclib as a new treatment option. The company plans to further explore synergistic combinations and will host a webcast on April 13, 2021, to discuss the findings and company updates.
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company, announced its participation in the 20th Annual Needham Virtual Healthcare Conference. The company will present a comprehensive overview and business update on April 12, 2021, at 12:45 p.m. Eastern Time. A live webcast can be accessed via MEI Pharma's website, with an archived replay available for 30 days post-event. MEI is focused on developing innovative cancer therapies, including zandelisib, currently in Phase 2 trials, aiming for FDA accelerated approval.
MEI Pharma, Inc. (NASDAQ: MEIP) announced that its abstract on Voruciclib, a CDK9 inhibitor, was selected for an E-Poster Session at the AACR Annual Meeting 2021, set for April 10, 2021. Voruciclib targets KRAS mutant cancers by downregulating MYC, which is crucial for cancer cell proliferation. Preclinical studies demonstrated reduced cell viability and significant tumor growth inhibition. MEI is also conducting additional studies to evaluate Voruciclib's synergistic effects with other KRAS inhibitors. This positions Voruciclib as a potential therapeutic option for challenging KRAS-driven cancers.
MEI Pharma (NASDAQ: MEIP) has confirmed its participation in the virtual H.C. Wainwright Global Life Sciences Conference 2021. The event will feature a company overview and business update, available for on-demand listening starting March 9, 2021, at 7:00 a.m. Eastern Time. This presentation will be archived for 90 days on MEI Pharma's website. The company is focused on developing new cancer therapies, including zandelisib, which is currently in a Phase 2 clinical trial potentially supporting FDA approval.
MEI Pharma (NASDAQ: MEIP) reported its financial results for the quarter ending December 31, 2020, showing significant developments in its zandelisib program. Cash and equivalents stood at $180.1 million, aided by $20.9 million from a tax refund. Revenue increased to $9.2 million from $1.0 million year-over-year, mainly due to a licensing agreement with Kyowa Kirin. Research and development expenses rose to $22.2 million, with a net loss of $11.5 million, improving from $20.2 million the previous year. The company anticipates important milestones for zandelisib in 2021.
MEI Pharma, Inc. (NASDAQ: MEIP) announced the completion of the safety evaluation phase in its Phase 1b trial for zandelisib, a selective PI3K delta inhibitor, in combination with zanubrutinib for B-cell malignancies. The Safety Review Committee recommended expanding into disease-specific cohorts, confirming the treatment was well tolerated. MEI also updated its 2021 pipeline milestones, including anticipated enrollment completion in the Phase 2 TIDAL study and initiation of further studies for zandelisib, voruciclib, and ME-344. The company has sufficient cash runway through 2023.
FAQ
What is the current stock price of Mei Pharma (MEIP)?
What is the market cap of Mei Pharma (MEIP)?
